Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Federica Cernuto, Avisa Maleki, Giulia Russo, Valentina Di Salvatore, Francesco Pappalardo
… 2025, using combinations of keywords such as epitope-based vaccines, reverse vaccinology, immunoinformatics, and immune system simulation. **EXPERT OPINION:** In silico approaches offer a transformative advantage to vaccine research by delivering speed, cost-efficiency, and enh…
Aishwarya Shaji, Akanksha Verma, Ashima Bhaskar, Ved Prakash Dwivedi
…r antigenicity in adults have evoked the need to design new vaccines against TB. The limited parameter is the availability of potent antigens; as a consequence, it is imperative to study the()-specific antigens that can provide a stronger immune response if included in vaccine ca…
Angela Hidalgo-Gajardo, Bryan Mangui, Carla Villavicencio, Jorge R Toledo, Frank Camacho
…tes the host immune response used as a component in subunit vaccines, either alone or in combination with other antigens. Incorporating this protein into new diagnostic, therapeutic, and vaccine strategies could optimize disease control. This review explores HspX's multifaceted r…
Justin Devine, Bart Jacobs, Isabel Leroux-Roels, Geert Leroux-Roels, Robbert van der Most
With ageing populations, the prevalence of different types of dementias is increasing. The pathology of Alzheimer's disease (AD), the most common form of dementia, has been linked to the presence of plaques and neurofibrillary tangles in the central nervous system of patients. Th…
Majid Eslami, Bahram Fadaee Dowlat, Shayan Yaghmayee, Anoosha Habibian, Saeedeh Keshavarzi, et al.
…ese technologies for strong, adaptable, globally accessible vaccines. This review emphasizes next-generation vaccines as foundational for future immunoprophylaxis, especially against emerging infectious diseases and cancer immunotherapy.
Mattie S M Timmer, Lisa M Connor, Bridget L Stocker
…al to exploit the MR1-MAIT cell axis for the development of vaccines against infectious disease. Within this context an MR1 ligand, typically 5-(2-oxopropylideneamino)-d-ribitylaminouracil (5-OP-RU), is administered with or without a Toll-like receptor (TLR) ligand or cytokine in…
Stefan H E Kaufmann
…d until immunity is weakened and TB disease develops. Novel vaccines are being developed mostly for adolescents and adults, but two live attenuated vaccines are currently assessed in infants in Phase III clinical trials. Globally, TB remains a major health threat and countries of…
Yunchang Yang, Yunqin Sun, Xinyao Kang, Yaofeng Wang
Messenger RNA (mRNA) vaccines have revolutionized the field of vaccinology, offering rapid design flexibility, scalable manufacturing, and strong immunogenicity. The unprecedented success of COVID-19 mRNA vaccines has accelerated research into novel delivery platforms and expande…
Sara Tengattini, Teodora Bavaro, Francesca Rinaldi, Caterina Temporini, Loredano Pollegioni, et al.
Tuberculosis (TB) has plagued humanity in numerous devastating forms for centuries and remains a significant health challenge. Mycobacterium tuberculosis (Mtb), the bacterium responsible for TB, was the leading cause of death among infectious agents until the COVID-19 pandemic em…
Yuho Horikoshi, Michiko Toizumi
Tuberculosis (TB) was a significant public health concern in Japan for over a century. While archaeological evidence suggests its presence as early as 1800 years ago, TB spread rapidly during Japan's modernization in the late 19th century. Initial control measures focused on…
Richard G White, Gavin J Churchyard, Katherine C Horton, Andrew Fiore-Gartland, Marcel A Behr, et al.
Current licensure trials of new vaccines to prevent tuberculosis disease use bacteriologically confirmed symptomatic tuberculosis disease as the primary endpoint. Globally, the incidence of symptomatic tuberculosis disease is low, making licensure trials large, long, and expensiv…
Jiazheng Wei, Junli Li, Xiaochi Li, Weixin Du, Cheng Su, et al.
…ol of TB. However, evaluating the protective efficacy of TB vaccines faces numerous challenges, particularly in the selection of animal models and bacterial strains. Variations in animal models, challenge strains, challenge routes, and doses can significantly impact the outcomes …
G V R Krishna Prasad, Jennifer A Philips
…monary tuberculosis (TB). Efforts to develop more effective vaccines are hindered by an incomplete understanding of the correlates of protection and by the pathogen's sophisticated immune-evasion strategies.systematically undermines host defenses, reprograms host cell biology, an…
Laura Mateu-Arrom, Lluis Puig
…general population, including annual influenza and COVID-19 vaccines. Live-attenuated vaccines are generally advised against in patients undergoing biologic treatment. However, some live-attenuated vaccines may be safely administered under specific circumstances with IL-17 or IL-…
Justice K. Boakye-Appiah, Belinda S. Hall, Rajko Reljić, Rachel E. Simmonds
Abstract Buruli ulcer (BU), one of the skin-related neglected tropical diseases (skin NTDs), is a necrotizing and disabling cutaneous disease caused by subcutaneous infection with Mycobacterium ulcerans. Leading on from the World Health Organization’s (WHO) establishment of a glo…
Elly van Riet, Björn Corleis, Birgitte K Giersing, Mark Hatherill, Erlina Burhan, et al.
…ccelerate the development of new, effective, and affordable vaccines that are urgently needed to eliminate tuberculosis globally. Since then, the pipeline has diversified, several candidates are currently in phase 3 clinical trials, and many low-income and middle-income countries…
Pere-Joan Cardona
…ction as a central biological constraint on prophylactic TB vaccines and support incorporating MCI models into preclinical pipelines to enhance predictive value and prioritize prevention of disease.
Young June Choe, Keun Ju Kim, Lay-Myint Yoshida, Michiko Toizumi, Yung-Ching Lin
The Bacille Calmette-Guérin (BCG) vaccine remains essential for preventing severe pediatric tuberculosis (TB). This review compares BCG policies in Korea, Japan, and Taiwan - three low-burden countries with differing strategies. Notably, Taiwan and Japan have delayed vaccina…
Niloufar Kavian, Kouji Kobiyama, Ken J Ishii, Cevayir Coban
…nges persist: malaria, HIV, and dengue lack fully effective vaccines, whereas influenza and tuberculosis face waning efficacy. Emerging pathogens and drug-resistant strains further highlight the need for improved vaccines, particularly those offering rapid deployment, broad immun…
Dylan Kain, David Michael Lewinsohn, Deborah Anne Lewinsohn
Tuberculosis (TB) is the leading cause of infectious disease-related death globally. Most TB vaccine strategies have focused on conventional CD4 T cell responses, but to date, these have failed to deliver durable sterilizing protection. Donor unrestricted T cells (DURTs), includi…
Emma Whitlow, Abu Salim Mustafa, Shumaila Nida Muhammad Hanif
Abstract Due to the shortcomings of currently available BCG vaccines, new strategies have been considered for the development of alternative vaccines against tuberculosis . Many candidate vaccines are in the pipeline with an aim to replace BCG or boost the effect of BCG for proph…
Mitra Ashayeripanah
…ion harbours latent Mycobacterium tuberculosis, yet current vaccines, including BCG, offer limited protection against latency or reactivation. Multi-stage or post-exposure vaccines targeting antigens expressed during these phases may mitigate TB burden. This review screens late-s…
Qamar Abuhassan, Mohamed Abu Shuheil, Narinderjit Singh Sawaran Singh, Praharshkumar B Raj, Subbulakshmi Ganesan, et al.
…lecular engineering and immunological mechanisms of mRNA TB vaccines, evaluating their capacity to address the unique challenges posed by the intracellular lifestyle of Mycobacterium tuberculosis (Mtb). mRNA platforms realistically offer superior endogenous antigen production for…
Dalin Di, Chun'e Gao, Yonggen Deng, Yuxia Li, Yanyan Zhang
Tuberculosis (TB) is a chronic infectious disease caused bythat poses major global health challenges. The Bacillus Calmette-Guérin (BCG) vaccine provides only limited protection against TB in adults and the current therapeutic regimens for TB are constrained by prolonged tre…
Zuber Peermohammed Shaikh, Satish Balkrishna Bhise
Nanoparticles-based biological products need to be explore for finding out newer adjuvants. Most of next generation adjuvants are in clinical trials. Vaccine funding agencies should consider and initiate specific funding programs for adjuvant science and clinical development; eve…